Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.51 |
| ▸ | PDE1B | Q01064 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PNP | P00491 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5452386 | 0.87 | ALDH1A1 (0.51) | ADORA2AADORA1PDE1BALDH1A1LMNA | |
| SCHEMBL5451833 | 0.86 | PDE10A (0.61) | PDE1BALDH1A1LMNASMN1; SMN2PDE10A | |
| SCHEMBL17283025 | 0.85 | ALDH1A1 (0.49) | ADORA2AADORA1PDE1BALDH1A1LMNA | |
| SCHEMBL6078154 | 0.84 | ALDH1A1 (0.48) | PDE1BALDH1A1LMNASMN1; SMN2PDE10A | |
| SCHEMBL29976787 | 0.82 | PDE1B (0.47) | ADORA2AADORA1PDE1BALDH1A1PDE10A | |
| SCHEMBL21174200 | 0.79 | TLR7 (0.57) | PDE1BALDH1A1LMNASMN1; SMN2PDE10A | |
| SCHEMBL5465848 | 0.79 | ADORA2A (0.52) | ADORA2AADORA1PDE1BALDH1A1PDE10A | |
| SCHEMBL17274869 | 0.76 | PDE10A (0.54) | ADORA2AADORA1PDE1BALDH1A1LMNA | |
| SCHEMBL5465357 | 0.75 | HPGD (0.64) | ALDH1A1LMNASMN1; SMN2KMT2AHPGD | |
| SCHEMBL18341924 | 0.74 | ALDH1A1 (0.46) | PDE1BALDH1A1LMNASMN1; SMN2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145512-B1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | JIANGSU HENGRUI MEDICINE CO (CN) | 2019-07-17 | — | — | EP | disclosed |
| EP-3145512-B1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | JIANGSU HENGRUI MEDICINE CO (CN) | 2019-07-17 | — | — | EP | disclosed |
| US-10144737-B2 | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-12-04 | — | — | US | disclosed |
| US-20170114063-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114063-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114063-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-04-27 | — | — | US | disclosed |
| EP-3145512-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| WO-2015178955-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2015-11-26 | — | — | WO | disclosed |
| WO-2015178955-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-20070203159-A1 | Purine compounds | UNIVERSITETET I OLSO (NO) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114063-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | BTK, BCL9, LCK | ADORA2A 4464/4885ADORA1 4804/4885PDE1B 1811/4885 |
| US-20070203159-A1 | Purine compounds | PNP, UMPS, TYMP | ADORA2A 96/4885ADORA1 149/4885PDE1B 3646/4885 |
| US-10144737-B2 | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | BTK, BCL9, LCK | ADORA2A 4464/4885ADORA1 4804/4885PDE1B 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.